Lupin may invest $50 million in Russian plant; Indian drugmakers doing well with ARVs
Indian drugmaker Lupin, is considering investing up to $50 million in the construction of a plant as well its R&D center in Russia by 2014, according to local sources.
The location of the plant has not been disclosed; however there is a possibility that it might be established in St Petersburg. The new plant is expected to focus on the production of anti-tuberculosis drugs, as well as galenical preparations and cephalosporin antibiotics.
Most of production of the future plant will be purchased by the Russian government with further supplies to Russian hospitals and other medical facilities. So far, up to 95% of all Lupin’s drugs are already purchased by the state.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze